Substance / Medication

Ketoconazole

Overview

Active Ingredient
ketoconazole
RxNorm CUI
6135

Indications

Pityrosporum orbiculare Malassezia furfur M. orbiculare . Ketoconazole shampoo, 2% is indicated for the treatment of tinea (pityriasis) versicolor caused by or presumed to be caused by(also known asor) Note: Tinea (pityriasis) versicolor may give rise to hyperpigmented or hypopigmented patches on the trunk which may extend to the neck, arms and upper thighs. Treatment of the infection may not immediately result in normalization of pigment to the affected sites. Normalization of pigment following

Labeler: ANI Pharmaceuticals, Inc.Updated: 2026-01-29T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Ketoconazole shampoo, 2% is contraindicated in persons who have known hypersensitivity to the active ingredient or excipients of this formulation.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

5 trials linked to this intervention

5
Total Trials
0
Recruiting
4
With Results

Research Evidence

Published studies and systematic reviews

Sort:
The Efficacy of Ketoconazole Containing Regimens in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Rehman Obaid Ur, Nadeem Zain Ali, Fatima Eeshal et al. · Clin Genitourin Cancer · 2024
PMID: 38296679Meta-Analysis
Ketoconazole as second-line treatment for Cushing's disease after transsphenoidal surgery: systematic review and meta-analysis.
Viecceli Camila, Mattos Ana Carolina Viana, Hirakata Vânia Naomi et al. · Front Endocrinol (Lausanne) · 2023
PMID: 37223017Meta-AnalysisFull text (PMC)
Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review.
Tresnanda Raden Indra, Pramod Sawkar Vijay, Safriadi Ferry · Asian Pac J Cancer Prev · 2021
PMID: 34710984Meta-AnalysisFull text (PMC)
Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review.
Fields Jaime R, Vonu Peter M, Monir Reesa L et al. · Dermatol Ther · 2020
PMID: 31858672Meta-Analysis
Topical ketoconazole: a systematic review of current dermatological applications and future developments.
Choi Franchesca D, Juhasz Margit L W, Atanaskova Mesinkovska Natasha · J Dermatolog Treat · 2019
PMID: 30668185Meta-Analysis
Ketoconazole associated hepatotoxicity: a systematic review and meta- analysis.
Yan Jiang Ying, Nie Xiao Lu, Tao Qing Mei et al. · Biomed Environ Sci · 2013
PMID: 23895707Meta-Analysis
Ketoconazole gel 2% in the treatment of moderate to severe seborrheic dermatitis.
Swinyer Leonard J, Decroix Jacques, Langner Andrzej et al. · Cutis · 2007
PMID: 17713152Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ketoconazole (substance)
SNOMED CT
387216007
UMLS CUI
C0022625
RxNorm CUI
6135
Labeler
ANI Pharmaceuticals, Inc.

Clinical Data

This intervention maps to 14 entities in the Ltrl knowledge graph.

14
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
5
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.